Guggenheim Has Started Edge Therapeutics (NASDAQ:EDGE) Stock Coverage With a “Buy” Rating and Target of $30.00

Edge Therapeutics (NASDAQ:EDGE) Price Target & New Coverage by Guggenheim

Expert analysts at Guggenheim has initiated coverage on shares of Edge Therapeutics (NASDAQ:EDGE) in a note sent to clients and investors on 26 October. The financial firm set “Buy” rating on the stock. Guggenheim’s price target of $30.00 suggests potential of 47.86% from the stock’s current stock price.

This entry was posted in Recent Development News: Q4 - 2015, Recent Developments. Bookmark the permalink.
Read Full Article »